# KROS (Keros Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Keros Therapeutics, Inc. reported $40.42M in revenue and a net loss of $61.73M for the trailing twelve months ended September 30, 2026 (up 183.3% year over year), with a -181.3% operating margin.

- Canonical: https://convexityos.com/fundamentals/KROS
- Markdown: https://convexityos.com/fundamentals/KROS.md
- SEC CIK: 0001664710
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:45 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001664710&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $40.42M | +183.3% YoY |
| Operating Income | TTM | -$73.27M | -181.3% margin |
| Net Income | TTM | -$61.73M | -152.7% net margin |
| Diluted EPS | TTM | -$3.03 | Split-adjusted |
| Free Cash Flow | TTM | -$48.27M | -119.4% FCF margin |
| Cash & ST Investments | Sep 30, 2026 | $259.5M | Total debt: $15.11M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $243.9M | $0 | $151K | $0 | $20.10M | $0 | $10.00M |
| Research & Development | $129.6M | $173.6M | $135.3M | $87.27M | $55.14M | $33.86M | $17.38M |
| Total Operating Expenses | $176.5M | $214.4M | $170.1M | $114.8M | $76.47M | $46.66M | $20.56M |
| **Operating Income** | $67.57M | -$210.8M | -$169.9M | -$114.8M | -$56.37M | -$46.66M | -$10.56M |
| **EBITDA** | $69.08M | -$209.6M | -$169.1M | -$114.1M | -$55.99M | -$46.38M | -$10.36M |
| Interest Expense | -- | $0 | $0 | $1.0K | $4.0K | $6.0K | -- |
| Income Before Tax | $91.90M | -$187.1M | -$153.0M | -$104.7M | -$56.73M | -$45.53M | -$12.34M |
| Income Tax Expense | $4.88M | $300K | $0 | $0 | $2.01M | -$172K | $0 |
| **Net Income** | $87.01M | -$187.4M | -$153.0M | -$104.7M | -$58.74M | -$45.36M | -$12.34M |
| Basic EPS | $2.34 | -$5.00 | -$5.20 | -$4.15 | -$2.52 | -$2.93 | -$6.08 |
| **Diluted EPS** | $2.30 | -$5.00 | -$5.20 | -$4.15 | -$2.52 | -$2.93 | -$6.08 |
| Basic Shares Outstanding | 37.2M | 37.4M | 29.4M | 25.2M | 23.3M | 15.5M | 2.3M |
| Diluted Shares Outstanding | 37.9M | 37.4M | 29.4M | 25.2M | 23.3M | 15.5M | 2.3M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $40.01M | $0 | $32K | $380K | $14.12M | $18.17M | $211.2M | $0 |
| Research & Development | $20.49M | $22.33M | $16.10M | $17.91M | $19.52M | $43.50M | $48.71M | $45.63M |
| Total Operating Expenses | $27.19M | $30.94M | $26.24M | $29.66M | $29.65M | $57.98M | $59.21M | $56.30M |
| **Operating Income** | $12.82M | -$30.94M | -$25.88M | -$29.27M | -$15.38M | -$39.82M | $152.0M | -$53.25M |
| **EBITDA** | $13.20M | -$30.54M | -$25.47M | -$28.87M | -$14.99M | -$39.45M | $152.4M | -$52.92M |
| Interest Income | $55K | -- | -- | -- | $0 | -- | -- | -- |
| Income Before Tax | $14.93M | -$28.71M | -$23.71M | -$24.98M | -$8.70M | -$32.92M | $158.5M | -$45.73M |
| Income Tax Expense | $772K | $0 | $0 | -$1.51M | -$1.42M | -$2.22M | $10.04M | $300K |
| **Net Income** | $14.15M | -$28.71M | -$23.71M | -$23.46M | -$7.28M | -$30.70M | $148.5M | -$46.03M |
| Basic EPS | $0.71 | -$1.45 | -$1.21 | -- | -$0.18 | -$0.76 | $3.66 | -- |
| **Diluted EPS** | $0.70 | -$1.45 | -$1.21 | -- | -$0.18 | -$0.76 | $3.62 | -- |
| Basic Shares Outstanding | 19.9M | 19.8M | 19.6M | -- | 40.6M | 40.6M | 40.6M | -- |
| Diluted Shares Outstanding | 20.3M | 19.8M | 19.6M | -- | 40.6M | 40.6M | 41.0M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M | $265.9M | $7.02M |
| **Cash & Short-Term Investments** | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M | $265.9M | $7.02M |
| Accounts Receivable, Net | $3.57M | $2.74M | $143K | $0 | $18.00M | $0 | -- |
| Other Current Assets | $2.40M | $1.45M | $1.00M | $276K | $210K | $160K | $215K |
| **Total Current Assets** | $315.4M | $588.9M | $347.3M | $285.8M | $251.4M | $267.7M | $8.93M |
| Property, Plant & Equipment, Net | $4.30M | $4.24M | $4.13M | $2.02M | $1.33M | $724K | $708K |
| Other Non-Current Assets | $0 | $2.06M | $2.05M | $2.12M | $82K | $0 | -- |
| **Total Non-Current Assets** | $22.59M | $26.99M | $22.73M | $21.01M | $3.81M | $1.72M | $2.03M |
| **Total Assets** | $338.0M | $615.9M | $370.0M | $306.8M | $255.3M | $269.4M | $10.96M |
| Accounts Payable | $1.97M | $4.60M | $5.45M | $3.34M | $3.65M | $2.15M | $2.09M |
| Deferred Revenue (Current) | -- | $0 | -- | -- | -- | -- | -- |
| Other Current Liabilities | $217K | $416K | $665K | $750K | $204K | $218K | $269K |
| **Total Current Liabilities** | $20.41M | $27.45M | $24.37M | $16.55M | $11.85M | $7.18M | $4.49M |
| Other Non-Current Liabilities | -- | -- | -- | -- | $0 | $62K | $119K |
| **Total Non-Current Liabilities** | $14.47M | $16.88M | $13.44M | $12.81M | $231K | $538K | $5.97M |
| **Total Liabilities** | $34.89M | $44.33M | $37.81M | $29.36M | $12.08M | $7.72M | $10.46M |
| **Total Debt (incl. Leases)** | $16.88M | $18.86M | $14.44M | $13.27M | $1.09M | $899K | $1.27M |
| Common Stock | $4.0K | $4.0K | $3.0K | $2.0K | $2.0K | $2.0K | $1.0K |
| Retained Earnings | -$481.8M | -$568.8M | -$381.4M | -$228.4M | -$123.8M | -$65.01M | -$19.65M |
| **Total Stockholders' Equity** | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M | $261.7M | -$19.45M |
| Total Equity | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M | $261.7M | -$19.45M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $259.5M | $257.6M | $281.5M | $287.4M | $693.5M | $690.2M | $720.5M | $559.9M |
| **Cash & Short-Term Investments** | $259.5M | $257.6M | $281.5M | $287.4M | $693.5M | $690.2M | $720.5M | $559.9M |
| Accounts Receivable, Net | $20.00M | $0 | $400K | $3.57M | $3.49M | $15.82M | $17.29M | $2.74M |
| Other Current Assets | $588K | $760K | $1.03M | $2.40M | $2.65M | $2.52M | $2.94M | $1.45M |
| **Total Current Assets** | $287.6M | $266.9M | $290.7M | $315.4M | $719.3M | $732.8M | $759.5M | $588.9M |
| Property, Plant & Equipment, Net | $3.39M | $3.71M | $3.96M | $4.30M | $4.56M | $4.84M | $4.47M | $4.24M |
| Other Non-Current Assets | $11K | -- | -- | $0 | $0 | $0 | $463K | $2.06M |
| **Total Non-Current Assets** | $19.74M | $20.72M | $21.62M | $22.59M | $23.48M | $24.36M | $25.05M | $26.99M |
| **Total Assets** | $307.4M | $287.6M | $312.3M | $338.0M | $742.8M | $757.2M | $784.6M | $615.9M |
| Accounts Payable | $3.79M | $1.82M | $1.49M | $1.97M | $2.30M | $5.27M | $6.64M | $4.60M |
| Deferred Revenue (Current) | -- | -- | -- | -- | $155K | $925K | $3.31M | $0 |
| Other Current Liabilities | $316K | $482K | $88K | $217K | $212K | $349K | $532K | $416K |
| **Total Current Liabilities** | $15.86M | $12.15M | $12.85M | $20.41M | $24.09M | $34.71M | $39.38M | $27.45M |
| **Total Non-Current Liabilities** | $12.41M | $13.13M | $13.81M | $14.47M | $15.11M | $15.72M | $16.31M | $16.88M |
| **Total Liabilities** | $28.27M | $25.28M | $26.66M | $34.89M | $39.20M | $50.43M | $55.69M | $44.33M |
| **Total Debt (incl. Leases)** | $15.11M | $15.72M | $16.31M | $16.88M | $17.43M | $17.95M | $18.41M | $18.86M |
| Common Stock | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K |
| Retained Earnings | -$520.0M | -$534.2M | -$505.5M | -$481.8M | -$458.3M | -$451.0M | -$420.3M | -$568.8M |
| **Total Stockholders' Equity** | $279.1M | $262.3M | $285.6M | $303.1M | $703.6M | $706.7M | $728.9M | $571.6M |
| Total Equity | $279.1M | $262.3M | $285.6M | $303.1M | $703.6M | $706.7M | $728.9M | $571.6M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | $87.01M | -$187.4M | -$153.0M | -$104.7M | -$58.74M | -$45.36M | -$12.34M |
| Depreciation & Amortization | $1.51M | $1.23M | $815K | $674K | $378K | $278K | $208K |
| Stock-Based Compensation | $28.70M | $34.87M | $28.76M | $18.68M | $11.72M | $4.10M | $59K |
| Change in Receivables | -$825K | -$2.60M | -$143K | $18.00M | -$18.00M | $0 | -- |
| Change in Payables | -$3.00M | -$249K | $1.61M | -$408K | $1.49M | $61K | $1.31M |
| **Operating Cash Flow** | $107.5M | -$160.9M | -$124.5M | -$70.06M | -$62.15M | -$36.89M | -$16.00M |
| Capital Expenditure | -$1.55M | -$1.93M | -$2.46M | -$1.24M | -$1.02M | -$294K | -$271K |
| **Free Cash Flow** | $106.0M | -$162.8M | -$127.0M | -$71.30M | -$63.17M | -$37.19M | -$16.27M |
| **Investing Cash Flow** | -$1.55M | -$1.93M | -$2.46M | -$1.24M | -$1.02M | -$294K | -$271K |
| Common Stock Issued | -- | -- | -- | -- | -- | $140.5M | $0 |
| Share Repurchases | -$375.0M | $0 | -- | -- | -- | -- | -- |
| **Financing Cash Flow** | -$378.5M | $391.8M | $179.0M | $120.3M | $28.55M | $296.0M | $14K |
| **Net Change in Cash** | -$272.5M | $229.0M | $51.98M | $49.01M | -$34.62M | $258.9M | -$16.25M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | $14.15M | -$28.71M | -$23.71M | -$23.46M | -$7.28M | -$30.70M | $148.5M | -$46.03M |
| Depreciation & Amortization | $384K | $402K | $403K | $400K | $395K | $370K | $344K | $332K |
| Stock-Based Compensation | $4.20M | $5.38M | $6.20M | $7.30M | $3.99M | $8.54M | $8.86M | $9.20M |
| Change in Receivables | -$20.00M | $400K | $3.17M | -$75K | $12.32M | $1.48M | -$14.55M | -$2.35M |
| Change in Payables | $1.97M | $323K | -$108K | -$697K | -$2.96M | -$1.37M | $2.02M | -$293K |
| **Operating Cash Flow** | $3.39M | -$20.42M | -$3.53M | -$27.29M | $3.25M | -$29.62M | $161.2M | -$46.01M |
| Capital Expenditure | -$59K | -$155K | -$73K | -$134K | -$132K | -$720K | -$565K | -$289K |
| **Free Cash Flow** | $3.33M | -$20.58M | -$3.60M | -$27.43M | $3.12M | -$30.34M | $160.6M | -$46.30M |
| **Investing Cash Flow** | -$59K | -$155K | -$73K | -$134K | -$132K | -$720K | -$565K | -$289K |
| **Financing Cash Flow** | -$1.47M | -$3.31M | -$2.32M | -$378.6M | $140K | $17K | $4.0K | $75.54M |
| **Net Change in Cash** | $1.86M | -$23.89M | -$5.92M | -$406.1M | $3.26M | -$30.33M | $160.6M | $29.25M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | 27.7% | -- | -112543.7% | -- | -280.5% | -- | -105.6% |
| **Net Profit Margin** | 35.7% | -- | -101319.2% | -- | -292.3% | -- | -123.4% |
| Return on Equity (ROE) | 28.7% | -32.8% | -46.1% | -37.7% | -24.2% | -17.3% | -- |
| Return on Assets (ROA) | 25.7% | -30.4% | -41.3% | -34.1% | -23.0% | -16.8% | -112.6% |
| Current Ratio | 15.45x | 21.45x | 14.25x | 17.27x | 21.23x | 37.27x | 1.99x |
| Quick Ratio | 14.25x | 20.50x | 13.59x | 16.86x | 20.94x | 37.01x | 1.56x |
| Debt to Equity | 0.06x | 0.03x | 0.04x | 0.05x | 0.00x | 0.00x | -- |
| **Revenue Growth (YoY)** | -- | -100.0% | -- | -100.0% | -- | -100.0% | -- |
| 5Y Revenue / Share Growth | -- | -100.0% | -- | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -181.3% | -698.0% | -337.4% | 27.7% | 17.9% | 0.1% | -4.9% | -- |
| **Net Profit Margin** | -152.7% | -572.1% | -260.4% | 35.7% | 26.5% | 8.2% | 2.0% | -- |
| Return on Equity (ROE) | -22.1% | -31.7% | -29.8% | 28.7% | 9.2% | 2.7% | 0.6% | -32.8% |
| Return on Assets (ROA) | -20.1% | -28.9% | -27.3% | 25.7% | 8.7% | 2.5% | 0.5% | -30.4% |
| Current Ratio | 18.14x | 21.96x | 22.62x | 15.45x | 29.86x | 21.11x | 19.29x | 21.45x |
| Quick Ratio | 17.62x | 21.20x | 21.93x | 14.25x | 28.93x | 20.34x | 18.74x | 20.50x |
| Debt to Equity | 0.05x | 0.06x | 0.06x | 0.06x | 0.02x | 0.03x | 0.03x | 0.03x |
| **Revenue Growth (YoY)** | +183.3% | -100.0% | -100.0% | -- | -- | -- | -- | -100.0% |
| Operating Income Growth (YoY) | -- | -- | -117.0% | -- | -- | -- | -- | -- |
| **Net Income Growth (YoY)** | -- | -- | -116.0% | -- | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | -- | -133.1% | -- | -- | -- | -- | -- |
| Operating Cash Flow Growth (YoY) | +4.3% | -- | -102.2% | -- | -- | -- | -- | -- |
| Free Cash Flow Growth (YoY) | +6.9% | -- | -102.2% | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
